$GDRX

GoodRx Holdings, Inc.

GoodRx operates a digital healthcare platform for consumers, healthcare providers, pharmacies, pharmacy benefit managers and pharmaceutical manufacturers in the United States. Its prescription marketplace lets consumers compare geographically relevant prices for generic and brand medications, access negotiated discounts with GoodRx codes, and find prescription-related services. GoodRx Care offers cash-pay telehealth, while subscriptions such as Gold and RxSmartSaver+ provide added savings and benefits. Condition-specific subscriptions bundle care and support for certain chronic conditions. Its Pharma Direct offering helps drug manufacturers advertise and integrate consumer affordability programs, and GoodRx Health provides health information. GoodRx is headquartered in Santa Monica, California. GoodRx earns fees or payments from pharmacy benefit managers when consumers use its codes to fill prescriptions, and from partner pharmacies for processing claims. It charges monthly or annual fees for subscription products and earns money by providing advertising and integrated affordability solutions for pharmaceutical manufacturers.

0
1
0

No SEC Form 4 filings for $GDRX in the last 30 days.

See all $GDRX insider activity →
Low

GoodRx agrees to $32M settlement. Who's eligible for money?

GoodRx agreed to a $32M settlement to resolve a class-action lawsuit alleging it shared users' health information with third parties. The settlement, pending court approval, covers users who used GoodRx services before April 20, 2024. Claims can be submitted until Dec. 29, with payments depending on the number of approved claims and court processes.

GoodRx stock rises on Google Cloud healthcare AI partnership

GoodRx Holdings (GDRX) stock rose 4.7% premarket after announcing a partnership with Google Cloud's Gemini for healthcare. The integration allows healthcare enterprises to access GoodRx pricing data within AI workflows, expanding distribution for GoodRx's prescription savings programs. The company plans to extend this integration to other AI platforms.

GoodRx earnings on deck amid accounting restatement concerns

GoodRx Holdings Inc. is set to report Q3 earnings, with investors focused on accounting errors that require restating first-half results. Analysts expect $201.93M revenue and $0.08 EPS, slightly down from Q2. The stock has a consensus price target of $3.95. The company's Pharma Direct segment understated revenue, raising concerns about internal controls and competition from the TrumpRx platform.

GDRX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning GDRX (GoodRx Holdings, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent GDRX coverage spans financial news, market movers and earnings.

What's driving GDRX

  • Settlement resolves alleged privacy violations and may reduce near-term legal overhang, but keeps focus on data-sharing practices and potential follow-on claims.

    finance.yahoo.com · Nov 18, 2026

  • The partnership expands GoodRx's distribution and could boost revenue, prompting short‑term buying interest.

    investing.com · Nov 10, 2026

  • GoodRx Holdings Inc. is set to report Q3 earnings, with investors focused on accounting errors that require restating first-half results. Analysts expect $201.93M revenue and $0.08 EPS, slightly down from Q2. The stock has a consensus price target of $3.95. The company's Pharma Direct segment understated revenue, raising concerns about internal controls and competition from the TrumpRx platform.

    investing.com · Nov 9, 2026

  • Positive price move driven by perceived regulatory stability.

    stockstory.org · Nov 4, 2026

  • The settlement is unlikely to affect GoodRx's valuation materially.

    openclassactions.com · Nov 1, 2026

AlphAI scores every news story that mentions GDRX with an AI model for sentiment and relevance, and aggregates insider trades from GoodRx Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GDRX

Score

GoodRx agrees to $32M settlement. Who's eligible for money?

GoodRx agreed to a $32M settlement to resolve a class-action lawsuit alleging it shared users' health information with third parties. The settlement, pending court approval, covers users who used GoodRx services before April 20, 2024. Claims can be submitted until Dec. 29, with payments depending on the number of approved claims and court processes.

GoodRx stock rises on Google Cloud healthcare AI partnership

GoodRx Holdings (GDRX) stock rose 4.7% premarket after announcing a partnership with Google Cloud's Gemini for healthcare. The integration allows healthcare enterprises to access GoodRx pricing data within AI workflows, expanding distribution for GoodRx's prescription savings programs. The company plans to extend this integration to other AI platforms.

GoodRx earnings on deck amid accounting restatement concerns

GoodRx Holdings Inc. is set to report Q3 earnings, with investors focused on accounting errors that require restating first-half results. Analysts expect $201.93M revenue and $0.08 EPS, slightly down from Q2. The stock has a consensus price target of $3.95. The company's Pharma Direct segment understated revenue, raising concerns about internal controls and competition from the TrumpRx platform.

GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare shares skyrocket, what you need to know

Shares of GoodRx, Evolent Health, UFP Technologies, Centene, and HCA Healthcare surged after Democrats regained majorities in Congress, easing drug pricing policy concerns. Analysts expect the biopharmaceutical sector to benefit from reduced regulatory uncertainty. UFP Technologies, up 21.5%, has seen significant volatility and strong performance, including a 51.1% year-to-date gain.

GoodRx Launches Employer Direct Weight Loss Offering

GoodRx launched Employer Direct, a weight loss offering for employers. It allows employers to select GLP-1 medications, set contribution levels, and add clinical care. The program includes medications like Wegovy and Zepbound, with manufacturer pricing. GoodRx collaborates with Novo and Lilly for employer pricing. The service aims to make GLP-1 treatments more accessible and affordable for employees.

Amazon (AMZN) and GoodRx (GDRX) Chase Prescription Subscribers as Insurance Coverage Slips

Amazon (AMZN) and GoodRx (GDRX) are offering flat-fee prescription plans targeting Americans with thinning insurance coverage. Amazon's plan starts at $5/month, while GoodRx's Companion plan costs $14.99/month and includes telehealth discounts. Both companies aim to secure recurring revenue, but GoodRx faces more pressure as its core business model is challenged. Amazon closed at $249.15 on September 30, up 13% YoY, while GoodRx closed at $3.29, down over 33% YoY.

GoodRx offers health subscription for families, to launch as employee benefit in 2027

GoodRx launched a family healthcare subscription, Companion, for $24.99/month, offering 250 generic medications and discounted medical services. The program will launch as an employer benefit in 2027. CEO Wendy Barnes cited rising healthcare costs and insurance gaps as key drivers. GoodRx's subscription revenue grew 39% YoY in Q2, with Companion uptake exceeding expectations. Employers expect healthcare costs to rise 9.2% in 2027, per the Business Group on Health.

Related tickers